CoChat
Sign Up
Cited by 529Gut microbiota and healthMetabolomics and Mass Spectrometry StudiesGastrointestinal motility and disorders

Functions of Gut Microbiota Metabolites, Current Status and Future Perspectives

Open access
Liu, Juan, Tan, Yuzhu, Cheng, Hao, Zhang, Dandan, Feng, Wuwen, Peng, Cheng·2022·Aging and disease
DOI 10.14336/ad.2022.0104PMC PMC9286904
Open this paper in CoChat — free accountOpen PDF

Abstract

Gut microbiota, a collection of microorganisms that live within gastrointestinal tract, provides crucial signaling metabolites for the physiological of hosts. In healthy state, gut microbiota metabolites are helpful for maintaining the basic functions of hosts, whereas disturbed production of these metabolites can lead to numerous diseases such as metabolic diseases, cardiovascular diseases, gastrointestinal diseases, neurodegenerative diseases, and cancer. Although there are many reviews about the specific mechanisms of gut microbiota metabolites on specific diseases, there is no comprehensive summarization of the functions of these metabolites. In this Opinion, we discuss the knowledge of gut microbiota metabolites including the types of gut microbiota metabolites and their ways acting on targets. In addition, we summarize their physiological and pathologic functions in health and diseases, such as shaping the composition of gut microbiota and acting as nutrition. This paper can be helpful for understanding the roles of gut microbiota metabolites and thus provide guidance for developing suitable therapeutic strategies to combat microbial-driven diseases and improve health.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14336/ad.2022.0104

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 178

  1. [1]Lagier JC, Dubourg G, Million M, Cadoret F, Bilen M, Fenollar F, et al (2018). Culturing the human microbiota and culturomics. Nat Rev Microbiol, 16: 540- 550. 29937540
  2. [2]Sekirov I, Russell SL, Antunes LC, Finlay BB (2010). Gut microbiota in health and disease. Physiol Rev, 90: 859- 904. 20664075
  3. [4]Feng WW, Liu J, Ao H, Yue SJ, Peng C (2020). Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs. Theranostics, 10: 11278- 11301. 33042283 PMC7532689
  4. [5]Vancamelbeke M, Vermeire S (2017). The intestinal barrier: a fundamental role in health and disease. Expert Rev Gastroenterol Hepatol, 11: 821- 834. 28650209 PMC6104804
  5. [6]Milshteyn A, Colosimo DA, Brady SF (2018). Accessing Bioactive Natural Products from the Human Microbiome. Cell Host Microbe, 23: 725- 736. 29902438 PMC7232905
  6. [7]Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S (2012). Host-gut microbiota metabolic interactions. Science, 336: 1262- 1267. 22674330
  7. [9]Lavelle A, Sokol H (2020). Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol, 17: 223- 237. 32076145
  8. [10]Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, et al (2019). Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol, 10: 277. 30915065 PMC6421268
  9. [11]Fan Y, Pedersen O (2021). Gut microbiota in human metabolic health and disease. Nat Rev Microbiol, 19: 55- 71. 32887946
  10. [13]Xu J, Chen HB, Li SL (2017). Understanding the molecular mechanisms of the interplay between herbal medicines and gut microbiota. Med Res Rev, 37: 1140- 1185. 28052344
  11. [15]Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L (2014). The role of short-chain fatty acids in health and disease. Adv Immunol, 121: 91- 119. 24388214
  12. [16]Felizardo RJF, Watanabe IKM, Dardi P, Rossoni LV, Câmara NOS (2019). The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids. Pharmacol Res, 141: 366- 377. 30639376
  13. [17]Canfora EE, Meex RC, Venema K, Blaak EE (2019). Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol, 15: 261- 273. 30670819
  14. [18]Tahara Y, Yamazaki M, Sukigara H, Motohashi H, Sasaki H, Miyakawa H, et al (2018). Gut microbiota-derived short chain fatty acids induce circadian clock entrainment in mouse peripheral tissue. Sci Rep, 8: 1395. 29362450 PMC5780501
  15. [19]Dalile B, Van Oudenhove L, Vervliet B, Verbeke K (2019). The role of short-chain fatty acids in microbiota-gut-brain communication. Rev Gastroenterol Hepatol, 16: 461- 478. 31123355
  16. [20]Feng WW, Ao H, Peng C (2018). Gut Microbiota, Short-Chain Fatty Acids, and Herbal Medicines. Front Pharmacol, 9: 1354. 30532706 PMC6265305
  17. [21]Pan LL, Li BB, Pan XH, Sun J (2021). Gut microbiota in pancreatic diseases: possible new therapeutic strategies. Acta Pharmacol Sin, 42: 1027- 1039. 33093569 PMC8209015
  18. [22]Wahlström A, Sayin SI, Marschall HU, Bäckhed F (2016). Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab, 24: 41- 50. 27320064
  19. [23]Poland JC, Flynn CR (2021). Bile acids, their receptors, and the gut microbiota. Physiology, 36: 235- 45. 34159805 PMC8526331
  20. [24]Govindarajan K, MacSharry J, Casey PG, Shanahan F, Joyce SA, Gahan CG (2016). Unconjugated bile acids influence expression of circadian genes: a potential mechanism for microbe-host crosstalk. PLoS One, 11: e0167319. 27907092 PMC5132238
  21. [26]Ostojic SM (2018). Inadequate production of H2 by gut microbiota and Parkinson disease. Trends Endocrinol Metab, 29: 286- 288. 29478695
  22. [27]McCarville JL, Chen GY, Cuevas VD, Troha K, Ayres JS (2020). Microbiota metabolites in health and disease. Annu Rev Immunol, 38: 147- 170. 32340573
  23. [28]Kalantar-Zadeh K, Berean KJ, Burgell RE, Muir JG, Gibson PR (2019). Intestinal gases: influence on gut disorders and the role of dietary manipulations. Nat Rev Gastroenterol Hepatol, 16: 733- 747. 31520080
  24. [29]Pacher P, Beckman JS, Liaudet L (2007). Nitric oxide and peroxynitrite in health and disease. Physiol Rev, 87: 315- 424. 17237348 PMC2248324
  25. [30]Singh SB, Lin HC (2015). Hydrogen sulfide in physiology and diseases of the digestive tract. Microorganisms, 3: 866- 889. 27682122 PMC5023273
  26. [31]Sen N (2017). Functional and molecular insights of hydrogen sulfide signaling and protein sulfhydration. J Mol Biol, 429: 543- 61. 28013031 PMC5276714
  27. [33]Zhang J, Zhu SW, Ma N, Johnston LJ, Wu CD, Ma X (2021). Metabolites of microbiota response to tryptophan and intestinal mucosal immunity: A therapeutic target to control intestinal inflammation. Med Res Rev, 41: 1061- 1088. 33174230
  28. [34]Modoux M, Rolhion N, Mani S, Sokol H (2021). Tryptophan metabolism as a pharmacological target. Trends Pharmacol Sci, 42: 60- 73. 33256987
  29. [35]Roager HM, Licht TR (2018). Microbial tryptophan catabolites in health and disease. Nat Commun, 9: 3294. 30120222 PMC6098093
  30. [38]Zhang YX, Wang Y, Ke BB, Du J (2021). TMAO: how gut microbiota contributes to heart failure. Transl Res, 228: 109- 125. 32841736
  31. [39]Yang SJ, Li XY, Yang F, Zhao R, Pan XD, Liang JQ, et al (2019). Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. Front Pharmacol, 10: 1360. 31803054 PMC6877687
  32. [40]Rudzki L, Stone T, Maes M, Misiak B, Samochowiec J, Szulc A (2021). Gut microbiota-derived vitamins-underrated powers of a multipotent ally in psychiatric health and disease. Prog Neuropsychopharmacol Biol Psychiatry, 107: 110240. 33428888
  33. [41]Stacchiotti V, Rezzi S, Eggersdorfer M, Galli F (2020). Metabolic and functional interplay between gut microbiota and fat-soluble vitamins. Crit Rev Food Sci Nutr, 1- 22. 32715724
  34. [42]Wang Y, Li N, Yang JJ, Zhao DM, Chen B, Zhang GQ, et al (2020). Probiotics and fructo-oligosaccharide intervention modulate the microbiota-gut brain axis to improve autism spectrum reducing also the hyper-serotonergic state and the dopamine metabolism disorder. Pharmacol Res, 157: 104784. 32305492
  35. [43]Morais LH, Schreiber HL, Mazmanian SK (2021). The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol, 19: 241- 55. 33093662
  36. [44]Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 56: 1761- 1772. 17456850
  37. [45]Serino M, Luche E, Gres S, Baylac A, Bergé M, Cenac C, et al (2012). Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut, 61: 543- 553. 22110050 PMC3292714
  38. [46]Donia MS, Fischbach MA (2015). Small molecules from the human microbiota. Science, 349: 1254766. 26206939 PMC4641445
  39. [47]Perruzza L, Gargari G, Proietti M, Fosso B, D’Erchia AM, Faliti CE, et al (2017). T follicular helper cells promote a beneficial gut ecosystem for host metabolic homeostasis by sensing microbiota-derived extracellular ATP. Cell Rep, 18: 2566- 2575. 28297661 PMC5368345
  40. [48]Mousa WK, Athar B, Merwin NJ, Magarvey NA (2017). Antibiotics and specialized metabolites from the human microbiota. Nat Prod Rep, 34: 1302- 1331. 29018846
  41. [50]Vijay N, Morris ME (2014). Role of monocarboxylate transporters in drug delivery to the brain. Curr Pharm Des, 20: 1487- 1498. 23789956 PMC4084603
  42. [51]Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT (1987). Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut, 28: 1221- 1227. 3678950 PMC1433442
  43. [52]Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L (2014). The role of short-chain fatty acids in health and disease. Adv Immunol, 121: 91- 119. 24388214
  44. [54]Jia W, Wei M, Rajani C, Zheng X (2021). Targeting the alternative bile acid synthetic pathway for metabolic diseases. Protein Cell, 12: 411- 425. 33252713 PMC8106556
  45. [55]Ikegami T, Honda A (2020). Reciprocal interactions between bile acids and gut microbiota in human liver diseases. J Hepatol, 72: 558- 577. 29150974
  46. [56]Winston JA, Theriot CM (2020). Diversification of host bile acids by members of the gut microbiota. Gut Microbes, 11: 158- 171. 31595814 PMC7053883
  47. [57]Smith EA, Macfarlane GT (1996). Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. J Appl Bacteriol, 81: 288- 302. 8810056
  48. [58]Ussher JR, Lopaschuk GD, Arduini A (2013). Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis, 231: 456- 461. 24267266
  49. [59]van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, et al (2019). Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nat Commun, 10: 310. 30659181 PMC6338741
  50. [60]Magnúsdóttir S, Ravcheev D, de Crécy-Lagard V, Thiele I (2015). Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. Front Genet, 6: 148. 25941533 PMC4403557
  51. [61]Wang L, Ravichandran V, Yin Y, Yin J, Zhang Y (2019). Natural products from mammalian gut microbiota. Trends Biotechnol, 37: 492- 504. 30392727
  52. [62]Behsaz B, Bode E, Gurevich A, Shi YN, Grundmann F, Acharya D, et al (2021). Integrating genomics and metabolomics for scalable non-ribosomal peptide discovery. Nat Commun, 12: 3225. 34050176 PMC8163882
  53. [63]Kenshole E, Herisse M, Michael M, Pidot SJ (2021). Natural product discovery through microbial genome mining. Curr Opin Chem Biol, 60: 47- 54. 32853968
  54. [64]Sun Y, O’Riordan MX (2013). Regulation of bacterial pathogenesis by intestinal short-chain fatty acids. Adv Appl Microbiol, 85: 93- 118 23942149 PMC4029053
  55. [65]Takeuchi T, Ohno H (2021). Reciprocal regulation of IgA and the gut microbiota: a key mutualism in the intestine. Int Immunol, dxab049. 34346497
  56. [66]Macia L, Tan J, Vieira AT, Leach K, Stanley D, Luong S, et al (2015). Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun, 6: 6734. 25828455
  57. [70]Adamowicz EM, Flynn J, Hunter RC, Harcombe WR (2018). Cross-feeding modulates antibiotic tolerance in bacterial communities. ISME J, 12: 2723- 2735. 29991761 PMC6194032
  58. [71]Zelezniak A, Andrejev S, Ponomarova O, Mende DR, Bork P, Patil KR (2015). Metabolic dependencies drive species co-occurrence in diverse microbial communities. Proc Natl Acad Sci U S A, 112: 6449- 6454. 25941371 PMC4443341
  59. [73]Wilkins LJ, Monga M, Miller AW (2019). Defining dysbiosis for a cluster of chronic diseases. Sci Rep, 9: 12918. 31501492 PMC6733864
  60. [74]Lee JH, Wood TK, Lee J (2015). Roles of indole as an interspecies and interkingdom signaling molecule. Trends Microbiol, 23: 707- 718. 26439294
  61. [75]Garcia-Gutierrez E, Mayer MJ, Cotter PD, Narbad A (2019). Gut microbiota as a source of novel antimicrobials. Gut microbes, 10: 1- 21. 29584555 PMC6363078
  62. [80]Zeng SL, Li SZ, Xiao PT, Cai YY, Chu C, Chen BZ, et al (2020). Citrus polymethoxyflavones attenuate metabolic syndrome by regulating gut microbiome and amino acid metabolism. Sci Adv, 6: eaax6208. 31922003 PMC6941918
  63. [81]Skrypnik K, Suliburska J (2018). Association between the gut microbiota and mineral metabolism. J Sci Food Agric, 98: 2449- 2460. 28991359
  64. [82]Whisner CM, Castillo LF (2018). Prebiotics, bone and mineral metabolism. Calcif Tissue Int, 102: 443- 79. 29079996 PMC5851694
  65. [83]Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al (2003). Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA, 289: 76- 79. 12503980
  66. [84]Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH (1999). The disease burden associated with overweight and obesity. JAMA, 282: 1523- 1529. 10546691
  67. [85]Pollock N, Grogan C, Perry M, Pedlar C, Cooke K, Morrissey D, et al (2010). Bone-mineral density and other features of the female athlete triad in elite endurance runners: a longitudinal and cross-sectional observational study. Int J Sport Nutr Exerc Metab, 20: 418- 426. 20975110
  68. [86]Kurpad AV, Muthayya S, Vaz M (2005). Consequences of inadequate food energy and negative energy balance in humans. Public Health Nutr, 8: 1053- 1076. 16277820
  69. [87]Moreno-Navarrete JM, Fernandez-Real JM (2019). The gut microbiota modulates both browning of white adipose tissue and the activity of brown adipose tissue. Rev Endocr Metab Disord, 20: 387- 397. 31776853
  70. [88]Jocken JW, González Hernández MA, Hoebers NT, van der Beek CM, Essers YP, Blaak EE, et al (2018). Short-chain fatty acids differentially affect intracellular lipolysis in a human white adipocyte model. Front Endocrinol, 8: 372. PMC5768634 29375478
  71. [90]Priyadarshini M, Villa SR, Fuller M, Wicksteed B, Mackay CR, Alquier T, et al (2015). An acetate-specific GPCR, FFAR2, regulates insulin secretion. Mol Endocrinol, 29: 1055- 1066. 26075576 PMC4484778
  72. [91]Pingitore A, Chambers ES, Hill T, Maldonado IR, Liu B, Bewick G, et al (2017). The diet-derived short chain fatty acid propionate improves beta-cell function in humans and stimulates insulin secretion from human islets in vitro. Diabetes Obes Metab, 19: 257- 265. 27761989
  73. [92]Frontera WR, Ochala J (2015). Skeletal muscle: a brief review of structure and function. Calcif Tissue Int, 96: 183- 195. 25294644
  74. [93]Zurlo F, Larson K, Bogardus C, Ravussin E (1990). Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest, 86: 1423- 1427. 2243122 PMC296885
  75. [94]Frampton J, Murphy KG, Frost G, Chambers ES (2020). Short-chain fatty acids as potential regulators of skeletal muscle metabolism and function. Nat Metab, 2: 840- 848. 32694821
  76. [95]Carley AN, Maurya SK, Fasano M, Wang Y, Selzman CH, Drakos SG, et al (2021). Short-chain fatty acids outpace ketone oxidation in the failing heart. Circulation, 143: 1797- 1808. 33601938 PMC8096711
  77. [96]Poll BG, Xu J, Jun S, Sanchez J, Zaidman NA, He X, et al (2021). Acetate, a short-chain fatty acid, acutely lowers heart rate and cardiac contractility along with blood pressure. J Pharmacol Exp Ther, 377: 39- 50. 33414131 PMC7985618
  78. [97]den Besten G, Lange K, Havinga R, van Dijk TH, Gerding A, van Eunen K, et al (2013). Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am J Physiol Gastrointest Liver Physiol, 305: G900- G910. 24136789
  79. [98]Den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk TH, et al (2015). Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation. Diabetes, 64: 2398- 2408. 25695945
  80. [99]Agus A, Clément K, Sokol H (2021). Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut, 70: 1174- 1182. 33272977 PMC8108286
  81. [100]Shapiro H, Kolodziejczyk AA, Halstuch D, Elinav E (2018). Bile acids in glucose metabolism in health and disease. J Exp Med, 215: 383- 396. 29339445 PMC5789421
  82. [101]Molinaro A, Wahlström A, Marschall HU (2018). Role of bile acids in metabolic control. Trends Endocrinol Metab, 29: 31- 41. 29195686
  83. [102]Cani PD, Van Hul M, Lefort C, Depommier C, Rastelli M, Everard A (2019). Microbial regulation of organismal energy homeostasis. Nat Metab, 1: 34- 46. 32694818
  84. [103]Jonsson AL, Bäckhed F (2017). Role of gut microbiota in atherosclerosis. Nat Rev Cardiol, 14: 79- 87. 27905479
  85. [104]Floyd JC, Fajans SS, Conn JW, Knopf RF, Rull J (1966). Stimulation of insulin secretion by amino acids. J Clin Invest, 45: 1487- 502. 5919350 PMC292828
  86. [105]Felig P, Marliss E, Cahill Jr GF (1969). Plasma amino acid levels and insulin secretion in obesity. N Engl J Med, 281: 811- 6. 5809519
  87. [106]Fontana L, Cummings NE, Apelo SI, Neuman JC, Kasza I, Schmidt BA, et al (2016). Decreased consumption of branched-chain amino acids improves metabolic health. Cell Rep, 16: 520- 530. 27346343 PMC4947548
  88. [107]Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al (2009). A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab, 9: 311- 26. 19356713 PMC3640280
  89. [108]Tajiri K, Shimizu Y (2018). Branched-chain amino acids in liver diseases. Transl Gastroenterol Hepatol, 3: 47. 30148232 PMC6088198
  90. [109]Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B (2017). Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology, 152: 1679- 94. 28214524
  91. [111]Zhu Y, Shui X, Liang Z, Huang Z, Qi Y, He Y, Chen C, et al (2020). Gut microbiota metabolites as integral mediators in cardiovascular diseases. Int J Mol Med, 46: 936- 48. 32705240 PMC7388831
  92. [112]Ðanić M, Stanimirov B, Pavlović N, Goločorbin-Kon S, Al-Salami H, Stankov K, et al (2018). Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome. Front Pharmacol, 9: 1382. 30559664 PMC6287190
  93. [113]Scaldaferri F, Pizzoferrato M, Gerardi V, Lopetuso L, Gasbarrini A (2012). The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol, 46: S12- 7. 22955350
  94. [114]Liu W, Luo X, Tang J, Mo Q, Zhong H, Zhang H, et al (2021). A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: By changing gut barrier. Eur J Nutr, 60: 2317- 30. 33180143
  95. [116]Wells JM, Brummer RJ, Derrien M, MacDonald TT, Troost F, Cani PD, et al (2017). Homeostasis of the gut barrier and potential biomarkers. Am J Physiol Gastrointest Liver Physiol, 312: G171- 93. 27908847 PMC5440615
  96. [117]Camilleri M (2019). Leaky gut: mechanisms, measurement and clinical implications in humans. Gut, 68: 1516- 26. 31076401 PMC6790068
  97. [118]Meddings J (2008). The significance of the gut barrier in disease. Gut, 57: 438- 40. 18334657
  98. [119]König J, Wells J, Cani PD, García-Ródenas CL, MacDonald T, Mercenier A, et al (2016). Human intestinal barrier function in health and disease. Clin Transl Gastroenterol, 7: e196. 27763627 PMC5288588
  99. [120]Wang HB, Wang PY, Wang X, Wan YL, Liu YC (2012). Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. Dig Dis Sci, 57: 3126- 35. 22684624
  100. [121]Sunkara LT, Jiang W, Zhang G (2012). Modulation of antimicrobial host defense peptide gene expression by free fatty acids. PLoS One, 7: e49558. 23166711 PMC3499459
  101. [122]Jung TH, Park JH, Jeon WM, Han KS (2015). Butyrate modulates bacterial adherence on LS174T human colorectal cells by stimulating mucin secretion and MAPK signaling pathway. Nutr Res Pract, 9: 343- 9. 26244071 PMC4523476
  102. [123]Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, et al (2015). Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol, 8: 80- 93. 24917457 PMC4263689
  103. [124]Biagioli M, Carino A, Cipriani S, Francisci D, Marchianò S, Scarpelli P, et al (2017). The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis. J Immunol, 199: 718- 733. 28607110
  104. [125]Di Lorenzo C, Youssef NN (2010). Diagnosis and management of intestinal motility disorders. Semin Pediatr Surg, 19: 50- 8. 20123274
  105. [126]Rao M (2020). An increasingly complex view of intestinal motility. Nat Rev Gastroenterol Hepatol, 17: 72- 3. 31811278
  106. [127]Verbeke KA, Boobis AR, Chiodini A, Edwards CA, Franck A, Kleerebezem M, et al (2015). Towards microbial fermentation metabolites as markers for health benefits of prebiotics. Nutr Res Rev, 28: 42- 66. 26156216 PMC4501371
  107. [129]Guarino MP, Cicala M, Putignani L, Severi C (2016). Gastrointestinal neuromuscular apparatus: An underestimated target of gut microbiota. World J Gastroenterol, 22: 9871- 9. 28018095 PMC5143755
  108. [130]Cherbut C, Aube AC, Blottiere HM, Galmiche JP (1997). Effects of short-chain fatty acids on gastrointestinal motility. Scand J Gastroenterol Suppl, 222: 58- 61. 9145449
  109. [131]Russell SL, Gold MJ, Hartmann M, Willing BP, Thorson L, Wlodarska M, et al (2012). Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep, 13: 440- 7. 22422004 PMC3343350
  110. [132]Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, et al (2014). Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med, 20: 159- 66. 24390308
  111. [133]Thorburn AN, McKenzie CI, Shen SJ, Stanley D, Macia L, Mason LJ, et al (2015). Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. Nat Commun, 6: 7320. 26102221
  112. [134]Trompette A, Gollwitzer ES, Pattaroni C, Lopez-Mejia IC, Riva E, Pernot J, et al (2018). Dietary fiber confers protection against flu by shaping Ly6c- patrolling monocyte hematopoiesis and CD8+ T cell metabolism. Immunity, 48: 992- 1005. 29768180
  113. [135]Dyson JK, Blain A, Shirley MD, Hudson M, Rushton S, Jones DE (2020). Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis. JHEP Rep, 3: 100202. 33474546 PMC7803647
  114. [136]Allen K, Jaeschke H, Copple BL (2011). Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol, 178: 175- 86. 21224055 PMC3070591
  115. [137]Gujral JS, Farhood A, Bajt ML, Jaeschke H (2003). Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. Hepatology, 38: 355- 63. 12883479
  116. [138]Fiorucci S, Biagioli M, Zampella A, Distrutti E (2018). Bile acids activated receptors regulate innate immunity. Front Immunol, 9: 1853. 30150987 PMC6099188
  117. [139]O'Brien KM, Allen KM, Rockwell CE, Towery K, Luyendyk JP, Copple BL (2013). IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis. Am J Pathol, 183: 1498- 507. 24012680 PMC3814525
  118. [140]Bence KK, Birnbaum MJ (2021). Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab, 50: 101143. 33346069 PMC8324696
  119. [141]Deng MJ, Qu F, Chen L, Liu C, Zhang M, Ren FZ, et al (2020). SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD. J Endocrinol, 245: 425- 37. 32302970
  120. [142]Peng J, Xiao X, Hu M, Zhang X (2018). Interaction between gut microbiome and cardiovascular disease. Life Sci, 214: 153- 7. 30385177
  121. [144]Zhang H, Meng J, Yu H (2017). Trimethylamine N-oxide supplementation abolishes the cardioprotective effects of voluntary exercise in mice fed a western diet. Front Physiol, 8: 944. 29218015 PMC5703864
  122. [145]Li X, Geng J, Zhao J, Ni Q, Zhao C, Zheng Y, et al (2019). Trimethylamine N-oxide exacerbates cardiac fibrosis via activating the NLRP3 inflammasome. Front Physiol, 10: 866. 31354519 PMC6634262
  123. [147]Behera J, Ison J, Tyagi SC, Tyagi N (2020). The role of gut microbiota in bone homeostasis. Bone, 135: 115317. 32169602 PMC8457311
  124. [148]Lu LY, Chen XX, Liu Y, Yu XJ (2021). Gut microbiota and bone metabolism. FASEB J, 35: e21740. 34143911
  125. [149]Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, et al (2009). Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A, 106: 3698- 703. 19234110 PMC2656143
  126. [150]Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D (2017). Gut microbiome in chronic kidney disease: challenges and opportunities. Transl Res, 179: 24- 37. 27187743 PMC5086447
  127. [151]Yang W, Cong Y (2021). Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases. Cell Mol Immunol, 18: 866- 77. 33707689 PMC8115644
  128. [152]Vázquez-Castellanos JF, Serrano-Villar S, Latorre A, Artacho A, Ferrus ML, Madrid N, et al (2015). Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol, 8: 760- 72. 25407519
  129. [153]Salem I, Ramser A, Isham N, Ghannoum MA (2018). The gut microbiome as a major regulator of the gut-skin axis. Front Microbiol, 9: 1459. 30042740 PMC6048199
  130. [155]Fung TC, Olson CA, Hsiao EY (2017). Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci, 20: 145- 55. 28092661 PMC6960010
  131. [158]Carloni S, Bertocchi A, Mancinelli S, Bellini M, Erreni M, Borreca A, et al (2021). Identification of a choroid plexus vascular barrier closing during intestinal inflammation. Science, 374: 439- 448. 34672740
  132. [159]Grab DJ, Perides G, Dumler JS, Kim KJ, Park J, Kim YV, et al (2005). Borrelia burgdorferi, host-derived proteases, and the blood-brain barrier. Infect Immun, 7: 1014- 22. PMC546937 15664945
  133. [160]Li HX, Sun J, Wang FY, Ding GQ, Chen WQ, Fang RC, et al (2016). Sodium butyrate exerts neuroprotective effects by restoring the blood-brain barrier in traumatic brain injury mice. Brain Res, 1642: 70- 78. 27017959
  134. [161]Dalile B, Van Oudenhove L, Vervliet B, Verbeke K (2019). The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol, 16: 461- 478. 31123355
  135. [163]Perry VH, Newman TA, Cunningham C (2003). The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci, 4: 103- 12. 12563281
  136. [164]Perry VH, Cunningham C, Holmes C (2007). Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol, 7: 161- 7. 17220915
  137. [165]Haghikia A, Jörg S, Duscha A, Berg J, Manzel A, Waschbisch A, et al (2015). Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity, 43: 817- 29. 26488817
  138. [166]Ochoa-Reparaz J, Mielcarz DW, Wang Y, Begum-Haque S, Dasgupta S, Kasper DL, et al (2010). A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol, 3: 487- 95. 20531465
  139. [167]Dong Y, Benveniste EN (2001). Immune function of astrocytes. Glia, 36: 180- 90. 11596126
  140. [168]Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Kenison JE, Mayo L, et al (2016). Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med, 22: 586- 97. 27158906 PMC4899206
  141. [170]Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, et al (2013). The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun, 4: 1829. 23652017 PMC3674247
  142. [171]Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SE, et al (2015). Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut, 64: 1744- 54. 25500202 PMC4680171
  143. [172]Lerche S, Brock B, Rungby J, Bøtker HE, Møller N, Rodell A, et al (2008). Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. Diabetes, 57: 325- 31. 17991759
  144. [174]Kim ER, Wu Z, Sun H, Xu Y, Mangieri LR, Xu Y, et al (2015). Hypothalamic non-AgRP, non-POMC GABAergic neurons are required for postweaning feeding and NPY hyperphagia. J Neurosci, 35: 10440- 50. 26203139 PMC4510285
  145. [175]Xu J, Bartolome CL, Low CS, Yi X, Chien CH, Wang P, et al (2018). Genetic identification of leptin neural circuits in energy and glucose homeostases. Nature, 556: 505- 9. 29670283 PMC5920723
  146. [176]Arnoriaga-Rodríguez M, Mayneris-Perxachs J, Burokas A, Pérez-Brocal V, Moya A, Portero-Otin M, et al (2020). Gut bacterial ClpB-like gene function is associated with decreased body weight and a characteristic microbiota profile. Microbiome, 8: 1- 0. 32354351 PMC7193372
  147. [177]Pearson JA, Wong FS, Wen L (2020). Crosstalk between circadian rhythms and the microbiota. Immunology, 161: 278- 90. 33090484 PMC7692254
  148. [178]Segers A, Depoortere I (2021). Circadian clocks in the digestive system. Nat Rev Gastroenterol Hepatol, 18: 239- 51. 33531700
  149. [179]Frazier K, Chang EB (2020). Intersection of the gut microbiome and circadian rhythms in metabolism. Trends Endocrinol Metab, 31: 25- 36. 31677970 PMC7308175
  150. [180]Matenchuk BA, Mandhane PJ, Kozyrskyj AL (2020). Sleep, circadian rhythm, and gut microbiota. Sleep Med Rev, 53: 101340. 32668369
  151. [181]Lopez DE, Lashinger LM, Weinstock GM, Bray MS (2021). Circadian rhythms and the gut microbiome synchronize the host’s metabolic response to diet. Cell Metab, 33: 873- 87 33789092
  152. [182]Crnko S, Du Pré BC, Sluijter JP, Van Laake LW (2019). Circadian rhythms and the molecular clock in cardiovascular biology and disease. Nat Rev Cardiol, 16: 437- 47. 30796369
  153. [183]Leng Y, Musiek ES, Hu K, Cappuccio FP, Yaffe K (2019). Association between circadian rhythms and neurodegenerative diseases. Lancet Neurol, 18: 307- 318. 30784558 PMC6426656
  154. [184]Codoñer-Franch P, Gombert M (2018). Circadian rhythms in the pathogenesis of gastrointestinal diseases. World J Gastroenterol, 24: 4297- 4303. 30344415 PMC6189841
  155. [185]Sancar A, Van Gelder RN (2021). Clocks, cancer, and chronochemotherapy. Science, 371: eabb0738. 33384351
  156. [187]Bishehsari F, Voigt RM, Keshavarzian A (2020). Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer. Nat Rev Endocrinol, 16: 731- 739. 33106657 PMC8085809
  157. [188]Leone V, Gibbons SM, Martinez K, Hutchison AL, Huang EY, Cham CM, et al (2015). Effects of diurnal variation of gut microbes and high-fat feeding on host circadian clock function and metabolism. Cell Host Microbe, 17: 681- 9. 25891358 PMC4433408
  158. [189]Segers A, Desmet L, Thijs T, Verbeke K, Tack J, Depoortere I (2019). The circadian clock regulates the diurnal levels of microbial short-chain fatty acids and their rhythmic effects on colon contractility in mice. Acta Physiol, 225: e13193. 30269420
  159. [191]Selmer T, Andrei PI (2001). P-Hydroxyphenylacetate decarboxylase from Clostridium difficile: A novel glycyl radical enzyme catalysing the formation of p-cresol. Eur J Biochem, 268: 1363- 72. 11231288
  160. [192]Bone E, Tamm A, Hill M (1976). The production of urinary phenols by gut bacteria and their possible role in the causation of large bowel cancer. Am J Clin Nutr, 29: 1448- 54. 826152
  161. [193]Hodgman MJ, Garrard AR (2012). A review of acetaminophen poisoning. Crit Care Clin, 28: 499- 516. 22998987
  162. [194]Laine JE, Auriola S, Pasanen M, Juvonen RO (2009). Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica, 39: 11- 21. 19219744
  163. [195]Li J, Chiew AL, Isbister GK, Duffull SB (2021). Sulfate conjugation may be the key to hepatotoxicity in paracetamol overdose. Br J Clin Pharmacol, 87: 2392- 2396. 33179287
  164. [196]Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, et al (2006). Human sulfotransferases and their role in chemical metabolism. Toxicol Sci, 90: 5- 22. 16322073
  165. [197]Raj GM, Raveendran Rs (2019). Introduction to Basics of Pharmacology and Toxicology. 1st ed. Singapore, Springer Nature.
  166. [198]Xie QS, Zhang JX, Liu M, Liu PH, Wang ZJ, Zhu L, et al (2021). Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine. Acta Pharmacol Sin, 42: 470- 81. 32555444 PMC8027219
  167. [199]Tolson AH, Wang H (2010). Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev, 62: 1238- 49. 20727377 PMC2991607
  168. [200]Dempsey JL, Cui JY (2019). Microbiome is a functional modifier of P450 drug metabolism. Curr Pharmacol Rep, 5: 481- 90. 33312848 PMC7731899
  169. [202]Manohar P, Loh B, Athira S, Nachimuthu R, Hua X, Welburn SC, Leptihn S (2020). Secondary bacterial infections during pulmonary viral disease: phage therapeutics as alternatives to antibiotics? Front Microbiol, 11: 1434. 32733404 PMC7358648
  170. [203]Mousa WK, Athar B, Merwin NJ, Magarvey NA (2017). Antibiotics and specialized metabolites from the human microbiota. Nat Prod Rep, 34: 1302- 31. 29018846
  171. [204]Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM (2017). Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol, 14: 356- 65. 28270698
  172. [205]Cheng H, Liu J, Tan Y, Feng WW, Peng C (2021). Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine. [J] Pharm Anal. PMC9463479 36105164
  173. [206]Kuntz TM, Gilbert JA (2017). Introducing the microbiome into precision medicine. Trends Pharmacol Sci, 38: 81- 91. 27814885
  174. [207]Baldi S, Menicatti M, Nannini G, Niccolai E, Russo E, Ricci F, et al (2021). Free fatty acids signature in human intestinal disorders: Significant association between butyric acid and celiac disease. Nutrients, 13: 742. 33652681 PMC7996737
  175. [208]Niccolai E, Baldi S, Ricci F, Russo E, Nannini G, Menicatti M, et al (2019). Evaluation and comparison of short chain fatty acids composition in gut diseases. World J Gastroenterol, 25: 5543. 31576099 PMC6767983
  176. [209]Emmi G, Bettiol A, Niccolai E, Ramazzotti M, Amedei A, Pagliai G, et al (2021). Butyrate-rich diets improve redox status and fibrin lysis in Behçet’s syndrome. Circ Res, 12: 278- 80. 33198585
  177. [210]Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, et al (2015). Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell, 163: 1585- 95. 26687352 PMC4871610
  178. [211]Ananthakrishnan AN, Luo C, Yajnik V, Khalili H, Garber JJ, Stevens BW, et al (2017). Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host Microbe, 21: 603- 10. 28494241 PMC5705050

Cited by

Sorted by citations

Authors
Liu, J., Tan, Y., Cheng, H., Zhang, D., Feng, W., & Peng, C.
Affiliations
Chengdu University of Traditional Chinese Medicine (CN)
Corresponding author
Peng, Cheng
ORCID
Venue
Aging and disease
Publisher
Aging and Disease
Published
2022
Volume
13
Issue
4
Pages
1106
ISSN
2152-5250 (ISSN-L)
DOI
10.14336/ad.2022.0104
PMC
PMC9286904
OpenAlex
W4285744692
Cited by
529
References
31
Citations by year
2026: 142 · 2025: 180 · 2024: 136 · 2023: 47 · 2022: 23 · 2020: 1
FWCI
31.60
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Aging and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (不。U19A2010, 81891012, 81891010, 82104409)
  • China Postdoctoral Science Foundation (2021M690490, U19A2010, 81891012)
  • Chengdu University of Traditional Chinese Medicine (U19A2010)
  • Chengdu University
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
gut microbiota metabolites, microbial metabolites, host-microbe interactions, gut microbiota composition, metabolic disorders, cardiovascular disease, gastrointestinal diseases, neurodegenerative diseases, cancer, treatment options

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review